Thus, we scored the total MAP1LC3B expression levels in all tissues and found that the MAP1LC3B levels were increased in tumor tissues compared with those in adjacent normal tissues in three major subsites of OSCC, including BMSCC (3.31 ± 1.44 vs. 2.30 ± 1.06, p < 0.001), TSCC (1.48 ± 1.02 vs. 0.59 ± 0.94, p < 0.001) and LSCC (3.14 ± 1.43 vs. 2.32 ± 0.71, p < 0.001) (Table 1). Here, MAP1LC3B is linked to neoplasm.